According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.9% and a 32.5% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Protagonist Therapeutics.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $119.36, implying a 53.3% upside from current levels. In a report issued on March 1, Robert W. Baird also maintained a Buy rating on the stock with a $110.00 price target.
The company has a one-year high of $101.24 and a one-year low of $61.31. Currently, Sarepta Therapeutics has an average volume of 968.9K.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year. Most recently, in December 2021, Kathleen Behrens, a Director at SRPT bought 5,000 shares for a total of $50,400.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Read More on SRPT:
- Leerink Partners Maintains Their Buy Rating on AstraZeneca (AZN)
- Deutsche Bank Thinks LANXESS’s Stock is Going to Recover
- J.P. Morgan Sticks to Their Hold Rating for Big Yellow Group (BYLOF)
- Canadian Energy Company Revisited by Wells Fargo Analyst
- Colliers Securities Keeps a Hold Rating on Electric Last Mile Solutions (ELMS)